Pbc and Ama—What Is the Connection?
1999; Lippincott Williams & Wilkins; Volume: 29; Issue: 1 Linguagem: Inglês
10.1002/hep.510290126
ISSN1527-3350
Autores Tópico(s)Pediatric Hepatobiliary Diseases and Treatments
ResumoHepatologyVolume 29, Issue 1 p. 271-276 Clinical ChallengeFree Access PBC and AMA—what is the connection? James Neuberger, Corresponding Author James Neuberger j.m.neuberger@bham.ac.uk Liver Unit, Queen Elizabeth Hospital, Birmingham, UK; and the Southampton University Hospitals, Southampton, UKLiver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. fax: 44-121-627-2449===Search for more papers by this authorRichard Thomson, Richard Thomson Department of Medicine, Southampton University Hospitals, Southampton, UKSearch for more papers by this author James Neuberger, Corresponding Author James Neuberger j.m.neuberger@bham.ac.uk Liver Unit, Queen Elizabeth Hospital, Birmingham, UK; and the Southampton University Hospitals, Southampton, UKLiver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. fax: 44-121-627-2449===Search for more papers by this authorRichard Thomson, Richard Thomson Department of Medicine, Southampton University Hospitals, Southampton, UKSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/hep.510290126Citations: 64AboutReferencesRelatedInformationPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessClose modalShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis 1997; 17: 13– 22.MEDLINE 2 Triger D. Primary biliary cirhosis: an epidemiological study. Brit Med J 1980; 281: 772– 775. 3 Brind A, Bray GP, Portmann BC, Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 1995; 36: 615– 617.MEDLINE 4 Mitchison HC, Bassendine M, Hendrick A. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986; 6: 1279– 1284.MEDLINE 5 Metcalf JV, Mitchison HC, Palmer J, Jones DE, Bassendine ME, James O. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399– 1402.MEDLINE 6 Heathcote EJ. Autoimmune cholangitis. Gut 1997; 40: 440– 442.MEDLINE 7 Kim WR, Poterucha J, Jorgensen R, Batts K, Homburger H, Dickson ER, Krom R, Wiesner R, Lindor K. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22– 26.MEDLINE 8 Kaserer K, Exner M, Mosberger I, Penner E, Wrba F. Characterisation of the inflammatory infiltrate in autoimmune cholangitis—a morphological and immunohistochemical study. Virchows Archiv 1998; 432: 217– 222.MEDLINE 9 Tsuneyama K, Van de Water J, van Thiel D, Coppel R, Ruebner B, Nakanuma Y, Dickson ER, Gershwin ME. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology 1995; 22: 1440– 1446.MEDLINE 10 Kitami N, Komada T, Ishii H. Immunological study of anti-M2 in mitochondrial antibody negative primary biliary cirrhosis. Intern Med 1995; 34: 496– 501.MEDLINE 11 Invernizzi P, Crosignani A, Battezzati P, Covini G, de Valle G, Larghi A, Zuin M, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090– 1095.MEDLINE 12 Mattalia A, Luttig B, Rosina F, Leung PS, Van der Water J, Bauducci M, Ciancio A, et al. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. J Autoimmun 1997; 10: 491– 497.MEDLINE 13 Micheletti P, Wanless IR, Katz A, Scheuer P, Yeaman S, Bassendine M, Palmer S, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct clinical syndrome of autoimmune cholangitis. Gut 1994; 35: 260– 265.MEDLINE 14 Mutimer D, Fussey S, Yeaman S, Kelly P, James O, Bassendine M. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989; 10: 403– 407.MEDLINE 15 Van Norstrand M, Malinchoc M, Lindor K, Therneau TM, Gershwin ME, Leung P, Dickson ER, Homburger HA. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997; 25: 6– 11.MEDLINE 16 Wozniak R, Bartnik E, Blobel G. Primary structure analysis of an integral membrane glycoprotein of the nuclear pore. J Cell Biol 1989; 108: 2083– 2092.MEDLINE 17 Bandin O, Courvalin J, Poupon R, Dubel L, Homberg J, Johannet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23: 1020– 1024.MEDLINE 18 Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashori Itoh T, Matsuda Y, et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastro Hepatol 1998; 13: 257– 265. 19 Wesierska-Gadek J, Honenauer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996; 110: 840– 847.MEDLINE 20 Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994; 106: 193– 199.MEDLINE 21 Luettig B, Boeker K, Schoessler W, Will H, Loges S, Schmidt E, Worman H, et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 1998; 28: 824– 828.MEDLINE 22 Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995; 23: 674– 680.MEDLINE 23 Lim AG, Jazrawi RP, Northfield T. The ursodeoxycholic acid story in primary biliary cirrhosis. Gut 1995; 37: 301– 304.MEDLINE 24 Neuberger J. Immune effects of ursodeoxycholic acid. In: P Berg, A Lohse, G Tiegs, A Wendel, eds. Autoimmune Liver Disease. Lancaster: Kluwer Academic Publishers. 1997; 93– 103. 25 Yamazaki K, Nakamura A, Abe S, Abe K, Suzuki K, Sato S. Disappearance of antimitochondrial antibody in primary biliary cirrhosis during long-term ursodeoxycholic acid treatment [Abstract]. Gastroenterology 1996; 110: A1364. 25a Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P, Coppel RA, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988; 141: 2321.MEDLINE 25b Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1(8594): 1067– 1070.MEDLINE 26 Yeaman SJ. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem J 1989; 257: 625– 632.MEDLINE 27 Jones DE, Palmer J, Yeaman S, James O, Bassendine M, Diamond AG. T-cell responses to components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995; 21: 995– 1002.MEDLINE 28 Joplin RE, Johnson GD, Matthews JB, Hamburger J, Lindsay JG, Hubscher SG, Strain A, et al. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary epithelium from patients with primary biliary cirrhosis. Hepatology 1994; 19: 1375– 1380.MEDLINE 29 Joplin R, Lindsay JG, Johnson G, Strain AJ, Neuberger J. Membrane dihydrolipoamide acetyl transferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. Lancet 1992; 339: 93– 94.MEDLINE 30 Van de Water J, Gerson LB, Ferrel LD, Lake JR, Coppel RL, Batts KP, Wiesner RH, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996; 24: 1079– 1084.MEDLINE 31 Tsuneyama K, Van de Water J, Nakanuma Y, Cha S, Ansari A, Coppel R, Gershwin ME. Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjogren's syndrome. Hepatology 1994; 20: 893– 898.MEDLINE 32 Krams SM, Surh CD, Coppel R, Ruebner B, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyl transferase, as a recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9: 411– 416.MEDLINE 33 Masanage T, Watanane Y, Leung PSC, Kamiyasu M, Tsuji K, Aisaka Y, Nakanishi T, et al. PBC-like lesion is induced and maintained by immunization with recombinant PDC-E2 BCKD-E2 hybrid molecule and liposaccharide injection in neonatally thymectomized mice [Abstract]. Gastroenterology 1994; 110: A1260. 34 Bassendine MF, Palmer J, Decruz D, McCaughan GW, Strickland DH, Sedgewick JD, Yeaman SJ, et al. Approaches to a murine model of AMA positive non-suppurative destructive cholangitis (NSDC) [Abstract]. J Hepatol 1998; 28(suppl 1): 59. 35 Ide T, Sata M, Suzuki H, Uchimura Y, Murashima S, Shirachi M, Tanikawa K. An experimental model of primary biliary cirrhosis induced by lipopolysaccharide and pyruvate dehydrogenase. Kurume Med J 1996; 43: 185– 188.MEDLINE 36 Gershwin ME, Mackay IR. Primary Biliary Cirrhosis: paradigm or paradox for autoimmunity? Gastroenterology 1991; 100: 822– 833.MEDLINE 37 Mitchison HC, Palmer J, Bassendine M, Watson AJ, Record CO, James OFW. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three year results. J Hepatol 1992; 15: 336– 344.MEDLINE 38 Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997; 100: 25– 31.MEDLINE 39 Nishio A, Van der Water J, Leung P, Joplin R, Neuberger J, Lake J, Bjorkland A, Totterman T, Peters M, Worman H, Ansari A, Coppel R, Gershwin ME. Comparative study of antimitochonrial antibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997; 25: 1085– 1089.MEDLINE 40 Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995; 69: 1339– 1343.MEDLINE 41 Gray MW. Origin and evolution of organelle genomes. Curr Opin Genet Dev 1993; 3: 884– 890.MEDLINE 42 Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, Coppel R, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91: 2653– 2664.MEDLINE 43 Joplin R, Wallace R, Lindsay JG, Palmer J, Yeaman S, Neuberger J. The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: pyruvate dehydrogenase X? Gastroenterology 1997; 113: 1727– 1733.MEDLINE 44 Harada K, Van de Water J, Leung PS, Coppel RL, Nakanuma Y, Gershwin ME. In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. Hepatology 1997; 25: 27– 32.MEDLINE 45 Danpure CJ. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1. J Nephrol 1998; 11(Suppl 1): 8– 12.MEDLINE 46 Tsuneyama K, Van de Water J, Leung PSC, Cha S, Nakanuma Y, Kaplan MM, de Lellis R, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995; 21: 1031– 1037.MEDLINE 47 Leon MP, Bassendine M, Wilson J, Ali S, Thick M, Kirby J. Immunogenicity of biliary epithelium: investigtaion of antigen presentation to CD4+ T cells. Hepatology 1996; 24: 561– 567.MEDLINE 48 Damico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Cllea F, Consoli G. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40: 2113– 2116.MEDLINE 49 Delpre G, Niv Y. Primary biliary cirrhosis occurring in a married couple [Abstract]. J Hepatol 1998; 26(Suppl 1): 232. 50 Watson P, Goss B, Angus P, Smallwood R. Low prevalence of primary biliary cirrhosis (PBC) in Victoria, Australia. Gut 1995; 36: 927– 930.MEDLINE 51 Anand A, Elias E, Neuberger J. End-stage primary biliary cirrhosis in a first generation migrant south Asian population. Eur J Gastroenterol Hepatol 1996; 8: 663– 666.MEDLINE 52 Dmitrewski J, Hubscher S, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis after liver transplantation: the effect of immunosuppression. J Hepatol 1996; 24: 253– 257.MEDLINE 53 Joplin R, Sadamoto T, Wallace L, Carman W, Mason A, Neuberger J. Evidence for a transmissable factor in primary biliary cirrhosis [Abstract]. J Hepatol 1998; 28(Suppl 1): 51. 54 Surh CD, Cooper AE, Coppel RL, Leung P, Ahmed A, Dickson ER, Gershwin ME. The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypep-tide in patients with primary biliary cirrhosis. Hepatology 1988; 8: 290– 295.MEDLINE 55 Thomson RK, Davis Z, Palmer J, Arthur M, Yeaman S, Chapman C, Spellerberg M, et al. Immunogenetic analysis of a panel of monoclonal IgG and IgM anti-PDC-E2/X antibodies derived from patients with primary biliary cirrhosis. J Hepatol 1998; 28: 582– 594.MEDLINE 56 Tsai SL, Lai MY, Chen DS. Analysis of rearranged T cell receptor (TCR) V beta transcripts in livers of primary biliary cirrhosis: preferential V beta usage suggests antigen-driven selection. Clin Exp Immunol 1996; 103: 99– 104.MEDLINE 57 Butler P, Hamilton-Miller JMT, McIntyre N, Burroughs A. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 1995; 36: 931– 934.MEDLINE 58 Hopf U, Mooller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Galanos C, Huhn D. Relation between Escherichia Coli R (rough) forms in gut, lipid A in liver and primary biliary cirrhosis. Lancet 1989; 2: 1419– 1422.MEDLINE 59 Fussey S, Lindsay JG, Fuller C, Perham R, Dale S, James O, Bassendine M, et al. Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology 1991; 13: 467– 474.MEDLINE 60 Vilagut L, Vila J, Vinas O, Pares A, Ginez AM, Jimenez de Anta MT, Rodes J. Cross-reactivity of anti-Mycobacterium gorgonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994; 21: 673– 677.MEDLINE 61 O'Donohue J, McFarlane B, Bomford A, Yates M, Willimas R. Antibodies to atypical mycobacteria in primary biliary cirrhosis. J Hepatol 1994; 21: 887– 889.MEDLINE 62 Mason AL, Xu L, Guo L, Monoz S, Jaspan J, Bryer-Ash M, Cao Y, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1988; 351: 1620– 1624. 63 Karlsom A, Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity. Semin Immunol 1998; 10: 25– 31.MEDLINE 64 Burroughs A, Sternberg MJ, Baum H. Molecular mimicry in liver disease. Nature 1992; 358: 377– 378.MEDLINE 65 Cha S, Leung PS, Van de Water J, Tsuneyama K, Joplin RE, Anasari AA, Nakanuma Y, et al. Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2). Proc Natl Acad Sci U S A 1996; 93: 10949– 10954.MEDLINE 66 Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437– 1441.MEDLINE Citing Literature Volume29, Issue1January 1999Pages 271-276 ReferencesRelatedInformation RecommendedThe future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBCWeijia Duan, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Xiaoming Wang, Yu Wang, Xinyan Zhao, Hong Ma, Xiaojuan Ou, Hong You, Jidong Jia, Hepatology CommunicationsA sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosisSabine Oertelt, Roman Rieger, Carlo Selmi, Pietro Invernizzi, Aftab A. Ansari, Ross L. Coppel, Mauro Podda, Patrick S.C. Leung, M. Eric Gershwin, HepatologyChanging nomenclature for PBC: From 'cirrhosis' to 'cholangitis'Ulrich Beuers, M. Eric Gershwin, Robert G. Gish, Pietro Invernizzi, David E.J. Jones, Keith Lindor, Xiong Ma, Ian R. Mackay, Albert Parés, Atsushi Tanaka, John M. Vierling, Raoul Poupon, HepatologyCharacterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individualsAnsgar W. Lohse M.D., Karl-Hermann Meyer zum Büschenfelde, Beate Franz, Stephan Kanzler, Guido Gerken, Hans-Peter Dienes, HepatologyCharacterization of recombinant monoclonal IgA anti—PDC‐E2 autoantibodies derived from patients with PBCNobuyoshi Fukushima, Greg Nalbandian, Judy Van De Water, Kandra White, Aftab A. Ansari, Patrick Leung, Thomas Kenny, Shizuo G. Kamita, Bruce D. Hammock, Ross L. Coppel, Freida Stevenson, Hiromi Ishibashi, M. Eric Gershwin, Hepatology
Referência(s)